Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
暂无分享,去创建一个
Turgay Ayer | Christopher R Flowers | C. Flowers | T. Ayer | Qiushi Chen | L. Nastoupil | Qiushi Chen | Loretta J Nastoupil | Adam C Rose | Adam C. Rose
[1] R. Pettengell,et al. PCN62 UTILITY ELICITATION IN PATIENTS WITH FOLLICULAR LYMPHOMA , 2006 .
[2] George A. Wells,et al. An Assessment of Methods to Combine Published Survival Curves , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[3] E. Arias. United States life tables, 2007. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[4] Christopher R Flowers,et al. Practical approach for using Medicare data to estimate costs for cost–effectiveness analysis , 2005, Expert review of pharmacoeconomics & outcomes research.
[5] R. Gascoyne,et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Leonard,et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Horning,et al. Follicular lymphoma: clinical features and treatment. , 2008, Hematology/oncology clinics of North America.
[8] M. Kaminski,et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J R Beck,et al. Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.
[10] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[11] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[12] D. Lubeck,et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma , 2008, Leukemia & lymphoma.
[13] A. Hagenbeek,et al. Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with 90Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT). , 2007 .
[14] J. Hornberger,et al. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy , 2012, Leukemia & lymphoma.
[15] M. Kaminski,et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] T. Illidge. Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Vose,et al. Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Issa,et al. Cost‐effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population‐based study , 2014, European journal of haematology.
[19] A. Hagenbeek,et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Fisher,et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Kersten,et al. Treatment strategies in advanced stage follicular lymphoma. , 2011, Best practice & research. Clinical haematology.
[22] B. Cheson. New response criteria for lymphomas in clinical trials. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] A. Hagenbeek,et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Swerdlow,et al. Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma , 2008, Clinical Cancer Research.
[25] D. Abbey,et al. Medicare Physician Fee Schedule. , 2023, JAMA.
[26] Mark Stevenson,et al. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. , 2012, Health technology assessment.
[27] A. Hagenbeek,et al. Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[28] Max Wolf,et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.
[29] J. Armitage,et al. A decade of progress in lymphoma: advances and continuing challenges. , 2010, Clinical lymphoma, myeloma & leukemia.
[30] L. Gordon,et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Freedman,et al. Follicular lymphoma: 2012 update on diagnosis and management , 2012, American journal of hematology.
[32] J. Hainsworth,et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. , 2009, Clinical lymphoma & myeloma.
[33] R. Marcus,et al. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] K. Fairman,et al. What Is the Price Benchmark to Replace Average Wholesale Price (AWP)? , 2010, Journal of managed care pharmacy : JMCP.
[35] Andrew Lister,et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.
[36] R. Advani,et al. ACR Appropriateness Criteria: Localized nodal indolent lymphoma. , 2013, Oncology.
[37] E. Deconinck,et al. Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma , 2010, PharmacoEconomics.
[38] S. Dewilde,et al. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales , 2014, Journal of medical economics.
[39] S. Pileri,et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). , 2008, The Lancet. Oncology.
[40] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[41] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[42] A. Ng,et al. Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease , 2007 .
[43] J. Martikainen,et al. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma. , 2012, Clinical therapeutics.
[44] M. Hansmann,et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] J. Cerhan,et al. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States , 2014, Cancer.